欢迎访问《现代生物医学进展》编辑部！

骨肉瘤为最常见的恶性骨肿瘤，多发于 10-25 岁青少年，恶性程度高，复发率，转移率，死亡率高。虽然骨肉瘤化学治疗的开展明显提高了骨肉瘤患者的生存率，但效果并不很令人满意。近些年来，随着分子生物学、分子遗传学的发展，人们已经越来越多的认识到，骨肉瘤的发生、发展及预后往往涉及多个基因的改变，包括致癌基因的表达及活化，抑癌基因的丢失及失活。本文通过查询近年大量国内外关于骨肉瘤癌基因方面的文献，分析与骨肉瘤发生、发展及预后密切相关的致癌基因及抑癌基因。希望通过对这些基因深入的探讨，为骨肉瘤的治疗寻找新的方向及新的潜在的治疗新靶点奠定理论基础。

英文摘要:

Osteosarcoma is the most common malignant bone tumour, with a peak incidence in children and young adolescents aged 10-25 years, osteosarcoma has a high malignant level, in mortality, local recurrence rate and the distant metastasis rate were higher. Though intensifying or modifying chemotherapy improved survival rate for patients with osteosarcoma, but the effect was unsatisfactory. In recent years, with the development of molecular biology and molecular genetics, more and more people have come to realize that the expression and regulation of certain genes may be involved in occurrence, development and prognosis of osteosarcoma, which include activation and expressions of oncogene, deletion and inactivationof anti-oncogene. This paper discusses oncogene and anti-oncogene with occurrence, development and prognosis of osteosarcoma, based on a large number of domestic and foreign documents and papers about osteosarcoma gene of analysis. It was from the study of these that offers new directions to find out a new target in the future treatments of osteosarcoma.

View Full Text View/Add Comment Download reader